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In Papua, Indonesia, the antimalarial susceptibility of Plasmodium vivax (n  216) and P. falciparum (n 
277) was assessed using a modified schizont maturation assay for chloroquine, amodiaquine, artesunate,
lumefantrine, mefloquine, and piperaquine. The most effective antimalarial against P. vivax and P. falciparum
was artesunate, with geometric mean 50% inhibitory concentrations (IC50s) (95% confidence intervals [CI]) of
1.31 nM (1.07 to 1.59) and 0.64 nM (0.53 to 0.79), respectively. In contrast, the geometric mean chloroquine
IC50 for P. vivax was 295 nM (227 to 384) compared to only 47.4 nM (42.2 to 53.3) for P. falciparum. Two factors
were found to significantly influence the in vitro drug response of P. vivax: the initial stage of the parasite and
the duration of the assay. Isolates of P. vivax initially at the trophozoite stage had significantly higher
chloroquine IC50s (478 nM [95% CI, 316 to 722]) than those initially at the ring stage (84.7 nM [95% CI, 45.7
to 157]; P < 0.001). Synchronous isolates of P. vivax and P. falciparum which reached the target of 40%
schizonts in the control wells within 30 h had significantly higher geometric mean chloroquine IC50s (435 nM
[95% CI, 169 to 1,118] and 55.9 nM [95% CI, 48 to 64.9], respectively) than isolates that took more than 30 h
(39.9 nM [14.6 to 110.4] and 36.9 nM [31.2 to 43.7]; P < 0.005). The results demonstrate the marked
stage-specific activity of chloroquine with P. vivax and suggest that susceptibility to chloroquine may be
associated with variable growth rates. These findings have important implications for the phenotypic and
downstream genetic characterization of P. vivax.
In vitro drug susceptibility assays assess antimicrobial activ-
ity in the absence of the confounding effects of the host. Al-
though such assays have become useful for monitoring the
antimalarial resistance of Plasmodium falciparum, the assay
has been of limited use with P. vivax. This is in part a conse-
quence of a perception of the importance of antimalarial drug
resistance with P. vivax, compounded by difficulties in stan-
dardizing a field-based assay. Over the last decade, a number
of clinical studies have demonstrated the emergence of high-
grade chloroquine resistance in Papua, Indonesia, and Papua,
New Guinea (1, 18, 21), and its spread to other regions of Asia
(6) and South America (20). However, assessment of the clin-
ical efficacy of antimalarial drugs against P. vivax infection is
confounded by the occurrence of both reinfections and re-
lapses, making the attributable fraction of recurrent infections
due to intrinsic parasite resistance difficult to gauge (2, 3, 10).
To confirm the emergence of the spread of antimalarial drug
resistance of P. vivax and to investigate alternative antimalarial
drugs, it is critical that a standardized in vitro assay be devel-
oped and validated. The aim of this study was to define the in
vitro susceptibility profiles of a range of antimalarial drugs and
to investigate the confounding factors that modulate the de-
rived estimate of drug efficacy.
MATERIALS AND METHODS
Field location and sample collection. Between March 2004 and May 2007,
Plasmodium isolates were collected from patients attending malaria clinics in
Timika, located in the southern part of Papua province, Indonesia. Timika is a
region of endemicity for multidrug-resistant strains of P. vivax and P. falciparum,
with a risk of treatment failure of 65% within 28 days after chloroquine mono-
therapy for P. vivax malaria and 48% failure after multidrug therapy with chlo-
roquine-sulfadoxine-pyrimethamine for P. falciparum malaria (16). In 2004,
treatment guidelines were changed accordingly to recommend an artemisinin
combination therapy for both P. falciparum and P. vivax infection, precluding
further clinical studies of the use of chloroquine monotherapy in this region (15).
Patients with symptomatic malaria who presented to an outpatient facility were
recruited into the study if they were singly infected with P. falciparum or with P.
vivax, with a parasitemia of between 2,000 l1 and 80,000 l1. Patients treated
with antimalarials in the previous 3 weeks were excluded from this study. Venous
blood (5 ml) was collected by venipuncture and, after the host white blood cells
were removed using a CF11 column, 2 ml of packed infected red blood cells were
divided as follows: 1 ml was cryopreserved in Glycerolyte 57 solution (Baxter,
Deerfield, IL), 200 l was spotted onto a filter paper, and 800 l was used for the
in vitro drug susceptibility assay. Since most patients were not enrolled in clinical
studies, the therapeutic response to treatment could not be determined.
In vitro drug susceptibility assay. The antimalarial susceptibility of P. vivax
and P. falciparum isolates was measured using a protocol modified from the
WHO microtest, as described previously (11, 19). Two hundred microliters of a
2% hematocrit blood medium mixture consisting of McCoy’s 5A medium and
20% AB human serum was added to each well of predosed drug plates. The
drug plates contained 11 serial concentrations of the antimalarials, with maxi-
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Research, P.O. Box 41096, Casuarina, Darwin, NT 0811 Australia. Phone:
61 8 8922 8197. Fax: 61 8 8922 8429. E-mail: rnp@menzies.edu.au.
 Published ahead of print on 7 January 2008.
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mum concentrations of 5,910 nM for chloroquine, 557 nM for amodiaquine, 93
nM for artesunate, 489 nM for lumefantrine, 338 nM for mefloquine, and 769 nM
for piperaquine. A candle jar was used to mature the parasites at 37.5°C (22 to
42 h). Incubation was stopped when 40% of ring-stage parasites had matured
to mature schizonts in the drug-free control. Preliminary studies demonstrated
that once the 40% schizont threshold had been reached, further incubation did
not increase the final count.
Thick blood films made from each well were stained with 5% Giemsa stain for
30 min and examined microscopically. Differential counts of 200 asexual para-
sites on the preincubation and test slides were divided into ring-stage parasites
(ring-shaped trophozoites and early amoebids without pigment), mature tropho-
zoites (in which single or double chromatin dot and hemozoin pigment were
visible), and schizonts. Free merozoites and gametocytes were not included in
the count. To ensure optimal maturity and ease of parasite identification and to
reduce the parasite classification error between microscopists, only schizonts
with at least five well-defined chromatin dots were classified as schizonts at
harvest.
The number of schizonts per 200 asexual-stage parasites was determined for
each drug concentration and normalized to the control well. The dose-response
data were analyzed using nonlinear regression analysis (WinNonLin version 4.1;
Pharsight), and the 50% inhibitory concentration (IC50) value was derived using
an inhibitory sigmoid Emax model. In vitro data were used only from predicted
curves where the Emax and E0 values were within 15% of 100 or 0, respectively.
Data analysis. Analysis was performed using SPSS software for Windows
(version 15; SPSS, Inc., Chicago, IL). The Mann-Whitney U test or the Kruskal-
Wallis method was used for nonparametric comparisons, and Student’s t test
(paired and unpaired) or one-way analysis of variance was used for parametric
comparisons of log-transformed data. For categorical variables, percentages and
corresponding 95% confidence intervals (CI) were calculated using Wilson’s
method. Proportions were examined using the 2 test with Yates’ correction or
by Fisher’s exact test.
Ethical approval. Ethical approval for this study was obtained from the ethics
committees of the National Institute of Health Research and Development,
Ministry of Health, Indonesia, and Menzies School of Health Research, Darwin,
Australia.
RESULTS
Between March 2004 and April 2007, venous blood was
collected from 493 patients with single-species infections of
either Plasmodium vivax (n  216) or P. falciparum (n  277)
and assayed for drug susceptibility. Adequate growth for har-
vest was achieved with 81% of isolates (401/493). Baseline
characteristics of the isolates processed are presented in Table
1. Whereas all P. falciparum isolates had ring-stage counts of
more than 80% prior to culture, the P. vivax isolates were
mostly asynchronous (median percentage of rings  36.5%
[interquartile range, 8 to 66%]) (Fig. 1). For those isolates that
reached harvest, the median duration of the assay was 26 h
(range, 24 to 48 h), with no differences between species. At
harvest, the mean percentage of schizonts in the culture was
43.3% (95% CI, 41.7 to 44.9) and did not differ between the
species of infection. The number of harvested isolates for
which the susceptibility data were rejected differed between
drug assays, varying from 0% (0/99) for mefloquine to 23%
(51/221) for chloroquine. The overall geometric mean IC50s
are presented in Table 2.
The time taken for P. vivax isolates to reach 40% schizonts,
and thus the duration of the assay, was correlated significantly
with the ratio of rings to trophozoites (the RT ratio) prior to
culture. The greater the initial proportion of trophozoites the
shorter the duration of the assay (Spearman correlation coef-
ficient, rs  0.485; P  0.001) (Fig. 2). Both the RT ratio and
the duration of the assay were negatively correlated with the
delay between venipuncture and setting the isolate up in cul-
ture (rs  0.171 and P  0.025; and rs  0.209 and P 
0.006, respectively). For the P. vivax isolates with a long delay
before processing (greater than 4 h), 84% (27/32) of the iso-
lates had a majority of parasites at the trophozoite stage (RT
1) at the time of culture, compared to 57% (80/140) of those
processed within 4 h (P  0.0077).
Initial stage of parasite and in vitro susceptibility. For P.
vivax, the RT ratio was correlated significantly with the IC50
values for chloroquine (rs  0.349; P  0.001), for amodia-
quine (rs  0.251; P  0.003), for artesunate (rs  0.162;
p  0.05), and for mefloquine (rs  0.258; P  0.007).
Compared to isolates for which the assay was set up predom-
inantly at the ring stage (RT  4), isolates set up predomi-
nantly at the trophozoite stage (RT  0.25) had significantly
higher geometric mean IC50 results for chloroquine (478 nM
versus 85.8 nM; P  0.001), amodiaquine (22.1 nM versus 10.0
nM; P  0.007), artesunate (1.61 nM versus 0.86 nM; P 
0.024), and mefloquine (17.0 nM versus 6.39 nM; P  0.001)
but not from lumefantrine or piperaquine.
To investigate the relationship between the stage of the
isolate and in vitro susceptibility, isolates with greater than
90% rings were set up in culture in the presence of the drug
directly and again after culture in the absence of the drug to
achieve 90% trophozoites. Plasmodium vivax isolates added to
TABLE 1. Baseline characteristics of isolates with which in vitro assay was attempted
Isolate
Total no. of
isolates
assayed
Total no. of isolates
harvested (% of
isolates)
Median (range) delay
from venipuncture to
start of culture (h)
Geometric mean
parasitemia (no. of
parasites/l
[95% CI])
% of patients receiving
antimalarial treatment
in previous 2 mo
(n/total)
Median initial % of
parasites at ring
stage (IQR)a
% of isolates with
an RT ratio of 1
(n/total)
P. vivax 216 175 (81) 2.00 (0.33–11.0) 7,338 (6,665–8,079) 25 (39/158) 36.5 (8–66) 37 (73/196)
P. falciparum 277 226 (82) 2.96 (0.17–11.3) 10,968 (9,862–12,187) 14 (32/224) 100 (100–100) 98 (222/227)
a Not available for 20 isolates. IQR, interquartile range.
FIG. 1. Histogram of the initial percentage of rings prior to culture.
Dark bars indicate P. vivax, and the light bar indicates P. falciparum.
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the assay at the ring stage had significantly lower chloroquine
IC50s than the same isolates added at the trophozoite stage
(median IC50 of 55.2 nM versus 2,812 nM, respectively; P 
0.008). P. falciparum isolates exposed at the ring stage to chlo-
roquine also resulted in lower IC50 values than those at the
trophozoite stage, although the difference was more modest
(median IC50 values of 36.1 versus 99.7 nM, respectively; P 
0.008 and P  0.04, respectively). The effect of the initial stage
of drug exposure for both P. vivax and P. falciparum was also
significant for amodiaquine but did not reach significance for
mefloquine (Table 3).
Duration of assay and in vitro susceptibility. The duration
of the assay was negatively correlated with the in vitro drug
susceptibility of chloroquine, amodiaquine, artesunate, and
mefloquine for both P. falciparum and P. vivax; this was inde-
pendent of the RT ratio and remained significant even after
parasites with an RT ratio greater than 4 were selected (see
Table 4). Of the 16 synchronous P. vivax isolates (RT  10)
with valid chloroquine IC50 data, the median duration of the
assay was 42 h (range, 24 to 48 h), with 31% (5/16) of the
isolates reaching the harvest criteria within 30 h. The geomet-
ric mean chloroquine IC50 value for fast-growing synchronous
parasites was 435 nM (95% CI, 169 to 1,118) compared to 39.9
nM (14.6 to 110.4) for isolates taking longer than 30 h (P 
0.005). Although the majority of P. falciparum isolates were
synchronous at the start of the assay, the duration of the assay
also ranged from 24 to 48 h, with 53% (83/155) of the isolates
reaching harvest within 30 h. Faster growing P. falciparum
parasites also had higher geometric mean chloroquine IC50
values (55.9 nM [95% CI, 48 to 64.9]) than the slower growing
parasites (36.9 nM [31.2 to 43.7]; P  0.001).
Stratified results of in vitro susceptibility of P. vivax. Using
criteria derived previously (23), P. vivax results were stratified
into four groups according to whether the parasites were set up
in culture with a majority of rings (RT  1) or a majority of
trophozoites (RT  1) and whether the duration of the assay
was below or above 30 h (Fig. 2). The stratified IC50 results are
presented in Table 5. For isolates which were predominantly at
the ring stage prior to culture (RT  1) (Fig. 2, quadrants B
plus C), the geometric mean IC50 estimates for P. vivax were
142 nM (95% CI, 90.4 to 222) for chloroquine, 11.8 nM (95%
CI, 8.6 to 16.2) for amodiaquine, 1.00 nM (95% CI, 0.70 to
1.42) for artesunate, 28.5 nM (95% CI, 15.6 to 51.8) for lume-
fantrine, 9.99 nM (95% CI, 6.98 to 14.3) for mefloquine, and
18.6 nM (95% CI, 14.0 to 24.6) for piperaquine. The correla-
tion coefficients for P. vivax and P. falciparum isolates are
presented in Table 6.
DISCUSSION
Unlike Plasmodium falciparum, P. vivax has a selective pref-
erence for invading young red cells (8), which has confounded
the development of a standardized in vitro drug susceptibility
assay. Susceptibility testing for P. vivax continues to rely on the
modifications of the schizont maturation test (4, 7, 9, 14, 19,
23), whereas assays used for P. falciparum are increasingly
incorporating red cell reinvasion and adopting alternative
methods of growth quantification. In the present study, we
compared the schizont maturation test for P. falciparum and P.
vivax isolates in Papua, Indonesia, where clinical multidrug
resistance of both species has emerged (16).
Whereas the isolates of P. falciparum were mostly syn-
chronous, those of P. vivax were predominantly asynchro-
nous, with all stages of the parasite present in the peripheral
blood. The asynchronicity of P. vivax is well documented
but, importantly, varies between areas of differing endemic-
ity, a factor recently found to confound the in vitro suscep-
tibility of chloroquine in both Thai and Indonesian isolates
(22). In view of the high proportion of patients with asyn-
chronous P. vivax infections in Papua, Indonesia, we
adopted an inclusive approach for parasite testing based on
the total parasitemia rather than the staging. As a conse-
FIG. 2. Scatter plot of the ratio of rings to trophozoites stages
present initially in P. vivax isolates relative to the time taken to reach
40% schizonts in the control wells.
TABLE 2. Overall in vitro sensitivity for each drug according to the species tested
Drug
P. vivax P. falciparum
No. of acceptable assays/
total no. of assays
harvested (%)a
Geometric mean IC50 value
(nM) (95% CI)
No. of acceptable assays/
total no. of assays
harvested (%)
Geometric mean IC50 value
(nM) (95% CI)
Chloroquine 155/170 (91.2) 295 (227–384) 170/221 (77) 47.4 (42.2–53.3)
Amodiaquine 143/144 (99.3) 15.4 (12.7–18.7) 120/137 (88) 5.59 (4.96–6.29)
Artesunate 136/149 (91.3) 1.31 (1.07–1.59) 127/157 (81) 0.64 (0.53–0.79)
Lumefantrine 54/64 (83) 19.3 (13.2–28.0) 101/124 (82) 10.2 (7.6–13.9)
Mefloquine 108/108 (100) 12.7 (10.3–15.5) 146/166 (88) 8.5 (6.98–10.4)
Piperaquine 125/137 (91.2) 21.9 (18.5–25.8) 165/200 (83) 14.5 (13.2–16.1)
a Values shown are the total number of assays with acceptable IC50 values/number of assays harvested.
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quence, more than 60% of the isolates that were tested had
a majority of trophozoites at the start of the assay. A major
finding of our analysis is that in vitro susceptibility was
correlated with the initial stage of the parasite, with isolates
predominantly at the trophozoite stage having a twofold
increase in IC50s compared to those of parasites predomi-
nantly at the ring stage. To assess the stage specificity of
drug activity further, synchronous isolates presenting with
more than 90% ring stage were exposed to the drug imme-
diately and after culturing to trophozoites in the absence of
the drug. Exposure at the trophozoite stage resulted in
higher IC50s to amodiaquine and chloroquine, although the
value did not reach statistical significance for mefloquine.
Our findings confirmed the absence of chloroquine activity
on P. vivax trophozoites, a developmental stage usually con-
sidered to be the specific target of this drug for P. falciparum
(25), and concur with those made by Powell and Berglund
some 30 years ago, using an in vitro MacroTest (13). Poten-
tially, these observations have important biological implica-
tions, highlighting a fundamental difference between the
activity of chloroquine with P. vivax and that with P. falcip-
arum.
For convenience, most schizont maturation assays adopt a
fixed duration of culture (usually 30 to 42 h) prior to the
quantification of parasite growth (4, 12, 24). However, the
time at which the assay is “harvested” is critical. Stopping
the culture early reduces the proportion of schizonts
present, thus decreasing the accuracy of quantification,
whereas extending the culture beyond schizogony results in
a significant reduction in the overall parasitemia as the
mature schizonts start to rupture. In contrast to other meth-
ods, we report an assay in which in vitro culture was main-
tained until a threshold of 40% schizonts had been reached
in the control wells. The time taken for isolates to reach this
target varied considerably for both P. vivax and P. falcipa-
rum, from 22 to 48 h, even when synchronous ring-stage
isolates were put into culture. The importance of this be-
came apparent in the significant correlation of the in vitro
susceptibility with the duration of the assay (Tables 4 and 5).
Assays of shorter duration had significantly higher chloro-
quine, amodiaquine, artesunate, and mefloquine IC50s than
assays of longer duration. Predictably, the initial stage of the
parasite was an important determinant of the time to har-
vest (rs  0.489; P  0.001); isolates at the trophozoite stage
had a shorter duration of assay (Fig. 2). However, the rela-
tion between the IC50s and the duration of the assay re-
mained after controlling for the initial stage of the parasite
(Table 4). Moreover, after highly synchronous cultures (RT
ratio  10) were selected, 31% of P. vivax assays and 53% of
P. falciparum assays were harvested within 30 h, and the
isolates with a short assay duration had a 10-fold and a
1.5-fold increase in chloroquine IC50, respectively, com-
pared to isolates with longer assay durations.
Our findings raise the possibility that chloroquine resis-
tant parasites grow faster than chloroquine susceptible par-
asites as has recently been reported in laboratory adapted
strains of P. falciparum (17). Alternatively isolates rapidly
reaching the threshold for harvest may represent parasites
initially at a more mature ring stage. These findings have
practical implications for interpreting in vitro assays and
relevance for resent attempts to develop a nonmicroscopy
assay. In assays that advocate culture for at least 36 h, faster
growing isolates will rupture prior to quantification and thus
will be recorded as unsuccessful. If these faster growing
parasites are intrinsically more resistant then this will sys-
tematically bias the assessment of in vitro susceptibility to-
ward a predominantly sensitive population. A recent com-
parison between Thai and Papuan isolates using the same
assay highlighted the problem. In Thailand, where P. vivax is
predominantly sensitive to chloroquine, the geometric mean
IC50 was reported as 46.8 nM (22). In Papua, chemothera-
peutic studies have confirmed high levels of clinical resis-
TABLE 3. In vitro susceptibility for paired isolates tested at both the ring and the trophozoite stagesa
Antimalarial
P. falciparum P. vivax
No. of
isolates
Median IC50
value (range)
at the ring stage
Median IC50
value(range) at the
trophozoite stage
P value No. ofisolates
Median IC50
value(range)
at the ring stage
Median IC50
value(range) at the
trophozoite stage
P value
Chloroquine 6 36.1 (11.9–55.0) 99.7 (19.6–157.8) 0.04 9 55.2 (18.3–171.8) 2812 (384–4611) 0.008
Amodiaquine 6 8.2 (2.6–16.2) 15.2 (5.9–22.4) 0.028 9 16.6 (6.7–37.9) 24.2 (12.5–59.9) 0.05
Mefloquine 6 4.6 (2.1–12.0) 6.4 (2.4–34.1) 0.075 9 7.9 (1.3–24.6) 12.5 (1.9–25.0) 0.123
a In vitro susceptibility for paired isolates was tested at both the ring (90%) stage and after culture in the absence of the drug to the trophozoite stage (90%).
TABLE 4. Correlation of in vitro susceptibility (IC50) with the duration of assay
Drug
P. falciparum All P. vivax P. vivax RT  4
rs value No. of isolates P value rs value No. of isolates P value rs value No. of isolates P value
Chloroquine 0.245 168 0.001 0.457 155 0.001 0.616 30 0.001
Amodiaquine 0.220 118 0.017 0.356 143 0.001 0.400 27 0.039
Artesunate 0.290 125 0.001 0.350 136 0.001 0.544 24 0.001
Lumefantrine 0.023 101 0.818 0.036 54 0.797 0.359 5 0.553
Mefloquine 0.340 144 0.001 0.413 108 0.001 0.381 20 0.097
Piperaquine 0.201 163 0.010 0.147 125 0.101 0.316 20 0.174
rs values indicate the Spearman rank correlation.
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tance to chloroquine (16). If we had adopted a criterion
based on the duration of the assay and initial parasite stag-
ing, then the derived estimate of IC50 would not have been
significantly different (59.8 nM) (Table 5). Applying a cri-
terion of selecting isolates with a majority of rings irrespec-
tive of the duration of the assay (i.e., quadrants B and C in
Table 5) yielded a significantly higher population mean (142
nM).
These data have relevance for the development of non-
microscopic methods for determining the in vitro suscepti-
bility of P. vivax, such as enzyme-linked immunosorbent
sensitivity or DNA detection (5). The absence of chloro-
quine sensitivity at the trophozoite stage combined with
minimal reinvasion and parasitemia, generally less than
0.5%, will both contribute to a poor signal-to-background
ratio, which are likely to undermine the sensitivity and re-
producibility of such assays (11).
Although population estimates of drug susceptibility
would best be based on isolates which are synchronous and
are initially exposed at the tiny ring stage, in practice, such
strict criteria are likely to exclude almost 90% of P. vivax
isolates, which in itself may constitute an appreciable bias.
Hence, to accommodate both the stage specificity of the
drug action and the possible confounding effects of the
speed of parasite growth, we recommend selecting parasites
with ring stage predominance (RT  1). Ensuring that iso-
lates are set up in culture within 2 h of venipuncture will
help to increase the proportion fulfilling this criterion. Al-
though the trophozoite minority will still contribute to the
schizont quantification, by 30 h of culture, most will have
ruptured, leaving those present at harvest to represent par-
asites exposed to the drug at all stages. Cultures should be
stopped upon reaching a certain threshold rather than used
in a fixed-duration assay, which has the potential to bias
toward sensitive isolates.
In conclusion, the primary objective of this study was to
TABLE 5. In vitro sensitivities of P. vivax, stratified by duration of assay and RT ratio prior to culturea
Drug
Quadrant A Quadrant B Quadrant C Quadrant D
P valuedNo. of
isolates
IC50 value(95% CI) for
trophozoite majority
and duration 30 hb
No. of
isolates
IC50 value (95% CI)
for ring majority
and duration
30 hc
No. of
isolates
IC50 value (95% CI) for
ring majority and
duration 30 hc
No. of
isolates
IC50 value (95% CI) for
trophozoite majority
and duration 30 hb
Chloroquine 18 298 (153–583) 35 59.8 (34.8–103) 25 475 (296–762) 75 539 (387–751) 0.001*
Amodiaquine 15 16.5 (9.8–27.9) 35 7.85 (5.31–11.6) 21 23.4 (15.6–35.0) 71 18.9 (14.2–25.0) 0.001*
Artesunate 14 1.20 (0.71–2.02) 32 0.83 (0.56–1.23) 18 1.39 (0.69–2.80) 71 1.60 (1.23–2.09) 0.06
Lumefantrine 6 32.9 (5.59–193) 5 37.6 (22.4–63.0) 10 24.8 (9.8–62.6) 33 14.6 (8.9–24.1) 0.296
Mefloquine 12 7.27 (3.84–13.8) 30 7.26 (4.89–10.8) 12 22.2 (11.7–42.2) 53 17.4 (13.5–22.4) 0.001**
Piperaquine 13 29.1 (22.3–38.1) 30 14.6 (10.3–20.7) 14 31.2 (20.9–46.5) 67 22.9 (17.9–29.3) 0.03***
a In vitro sensitivity of P. vivax for each drug (geometric mean IC50 95% CI	) stratified by the duration of assay and the RT ratio prior to culture. Quadrants are
the same subgroups as represented in Fig. 2.
b RT  1; data on the initial parasite stage was unavailable for 20 isolates.
c RT  1; data on initial RT ratios were missing for two isolates.
d Overall between-group differences, by analysis of variance: *, group B versus A, C, or D, P  0.001; **, group A or B versus C or D, P  0.006; ***, group B versus
A, C, or D, P  0.026.
TABLE 6. Correlation coefficients for the in vitro antimalarial susceptibilities of P. falciparum and P vivaxa
Antimalarial Combination
P. Falciparum P. Vivax
Correlation (rs) P value df Correlation P value df
Chloroquine Amodiaquine 0.648 0.001 119 0.698 0.001 51
Artesunate 0.596 0.001 111 0.285 0.05 46
Lumefantrine 0.427 0.001 65 0.104 0.735 12
Mefloquine 0.445 0.001 136 0.618 0.001 38
Piperaquine 0.347 0.001 139 0.620 0.001 40
Amodiaquine Artesunate 0.673 0.001 119 0.743 0.001 48
Lumefantrine 0.571 0.006 21 0.277 0.438 9
Mefloquine 0.386 0.001 112 0.703 0.001 41
Piperaquine 0.444 0.001 115 0.766 0.001 41
Artesunate Lumefantrine 0.030 0.879 27 0.112 0.793 7
Mefloquine 0.340 0.001 118 0.609 0.001 39
Piperaquine 0.422 0.001 115 0.432 0.005 39
Lumefantrine Mefloquine 0.016 0.914 50 0.702 0.504 2
Piperaquine 0.152 0.215 67 0.697 0.124 5
Mefloquine piperaquine 0.225 0.011 125 0.644 0.001 40
a Correlation coefficients (rs) are shown for the in vitro antimalarial susceptibility of P. falciparum and P vivax. P. vivax isolates shown are restricted to those with a
RT  1.
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determine the major factors underlying P. vivax drug suscep-
tibility, using a schizont maturation assay. Although we have
demonstrated that this method can be used to discriminate
between resistant and sensitive populations of P. vivax (22), the
derived IC50 value needs to be interpreted in conjunction with
the initial stage of the parasite as well as the duration of the
assay.
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